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Abstract
Rapidly progressive glomerulonephritis (RPGN) results from severe crescentic damage to glomeruli
and leads to irreversible kidney failure if not diagnosed and managed in a timely fashion. Tradition-
al treatment has relied on glucocorticoids and cyclophosphamide, with additional plasmapheresis
for certain conditions. Here we describe updates in the management of RPGN, according to the
underlying renal pathology. However, there remains a paucity of trials that have enrolled patients
with more advanced renal disease, dialysis dependence or with RPGN, and we are therefore still
reliant on extrapolation of data from studies of patients with a less severe form of disease. In add-
ition, reporting bias results in publication of cases or cohorts showing beneﬁt for newer agents in
advanced disease or RPGN, but it remains unclear how many unsuccessful outcomes in these cir-
cumstancestake place. Since clinical trials speciﬁcally in RPGN are unlikely, use of biologic registries
or combination of sufﬁcient sized cohort series may provide indications of beneﬁt outside of a clin-
ical trial setting and should be encouraged, in order to provide some evidence for the efﬁcacy of
therapeutic regimens in RPGN and advanced renal disease.
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Introduction
Rapidly progressive glomerulonephritis (RPGN) is clinical
syndrome deﬁned by the rapid loss of renal function, ac-
companied by features of a nephritic syndrome with pro-
teinuria, glomerular haematuria and often oliguria.
Although relatively uncommon, early recognition and
prompt diagnosis and treatment are crucial to prevent
irreversible loss of renal function. Histologically, RPGN is
characterized by a crescentic glomerulonephritis (CGN),
which is due to severe glomerular injury, resulting in
rupture of the glomerular capillary loops (Figure 1), with
accumulation of leucocytes and blood constituents in
Bowman’s space, which in turn induces visceral epithelial
cell proliferation, together forming a cellular crescent. CGN
is deﬁned pathologically (for most glomerular diseases)
when >50% of glomeruli have crescents, which are identi-
ﬁed on light microscopy by the presence of at least two
layers of cells in Bowman’s space. However, this cut-off is
arbitrary and clearly severe glomerular injury can occur
and result in a rapid decline of renal function with a lower
proportion of crescents. There are other conditions that
can lead to a clinical syndrome of RPGN, which are not
caused by severe glomerular. These include thrombotic
microangiopathies and rarely cases of tubulointerstitial
nephritis, making it important to make a ﬁrm diagnosis
based on clinical, haematological, serological and renal
biopsy data (Table 1).
CGN is commonly categorized based on the pattern of
immunoglobulin deposition by immunohistochemistry,
and is most frequently caused by:
￿ Anti-glomerular basement membrane (GBM) disease
with linear immunoglobulin deposition.
￿ Immune complex glomerulonephritis with granular im-
munoglobulin deposition.
￿ Pauci-immune glomerulonephritis most often asso-
ciated with anti-neutrophil cytoplasm antibody (ANCA).
The relative likelihood of each of these is dependent on
the age of the patient, with pauci-immune (ANCA asso-
ciated) GN being more common in older patients and
immune complex disease predominating in younger sub-
jects, as a result of the propensity for IgA nephropathy
(IgAN) post-infectious GN and lupus nephritis (LN) to
affect younger patients.
Management of these conditions is based on the under-
lying aetiology; however, in many instances, due to lack
of data, treatment strategies are extrapolated from one
indication to another, based on the common clinical pres-
entation and pathology with CGN. In addition, for many
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Advance Access publication 19 February 2015of the conditions, clinical trials have speciﬁcally excluded
patients with RPGN, and again extrapolations regarding
management in this group have to be made. The most
detailed and relevant trial data for patients with RPGN
comes from studies in ANCA-associated vasculitis (AAV),
while smaller cohort data are available for patients with
RPGN and underlying lupus nephritis, anti-GBM disease
and IgA nephropathy. As a result, various conditions that
present with RPGN may be treated with a similar type
of regimen, using combinations of immunosuppressive
agents, and adjunctive therapies; however, speciﬁcd o s i n g
protocols may vary. Newer agents that have reached the
clinic for one indication may well be/have been applied to
others, while there are other agents, effective in animal
models, that haveyet to be translated to the clinical setting.
Historically, the standard of care has been gluco-
corticoids, delivered as pulsed therapy and followed by
oral treatment, in combination with cyclophosphamide;
however, there remains much uncertainty about the
most efﬁcacious and least toxic steroid doses and how
they may be best used in combination with other newer
agents. In addition, the desire to minimise cumulative
doses of cyclophosphamide, especially in younger pa-
tients, has led to the trialling of other induction therapies.
This review will highlight the most recent developments in
the management of RPGN, with emphasis on the different
approaches in particularclinical settings.
Small vessel (ANCA associated) vasculitis and
pauci-immune CGN
Standard induction therapy has been with cyclophospha-
mide, given orally or pulsed intravenously, with glucocorti-
coids. Recent trials have investigated alternative induction
therapies. However, many of these studies have included
patients without renal involvement, or with less severe
renal impairment, limiting their utility to translate for pa-
tients with RPGN.
Rituximab
Rituximab is now ﬁrmly established as an option in the
management of AAV, and offers a viable alternative for
patients with a contraindication to cyclophosphamide. Two
landmark trials demonstrated non-inferiority in comparison
with cyclophosphamide and glucocorticoids in remission in-
duction. Evidence from the RAVE study (n= 197) demon-
strated that remission maintenance with rituximab and
glucocorticoid induction was as effective as cyclophospha-
mide induction followed by azathioprine and that patients
with relapsing disease beneﬁted more from rituximab.
However, only two-thirds of patients in this study had renal
involvement, and those with creatinine >354 μmol/L were
speciﬁcally excluded [1]. In the RITUXIVAS trial (n=44),
which included 33 patients treated with rituximab, all of
whom had some degree of renal impairment (median eGFR
20 mL/min/1.73 m
2, 24% dialysis dependent), there were
similar outcomes and adverse events compared with those
treated with conventional cyclophosphamide and gluco-
corticoid induction therapy [2].
A recent report in abstract form examined the outcome
of 28 patients presenting with advanced kidney disease
(eGFR <20 mL/min/1.73 m
2) who were treated with either
rituximab and glucocorticoids (n=9) or rituximab, gluco-
corticoids and cyclophosphamide (n=19 ) [3]. Outcomes
with regard end-stage renal disease (ESRD), death, im-
provement in renal function and infectious complications
were equivalent in these two small cohorts. A larger cohort
analysis is clearly required; until then, the long-term
beneﬁt of using rituximab without cyclophosphamide in
patients with RPGN oradvanced renal failure is uncertain.
Mycophenolate Mofetil
Mycophenolate mofetil (MMF) is appealing as a cyclophos-
phamide-sparing agent in AAV; however, no trials have in-
cluded patients with advanced renal impairment or RPGN.
A randomized, single-centre trial comparing MMF with
cyclophosphamide induction in 35 patients with creatinine
<500 μmol/L (mean 312 μmol/L) demonstrated a beneﬁt
for MMF, with regards rates of remission, reduction in Bir-
mingham Vasculitis Activity Score (BVAS) and improve-
ment in renal function [4]. A pilot study in the USA
reported remission induction in 76% of patients with mild-
to-moderate renal involvement (creatinine <240 μmol/L)
[5], while an open-label randomised controlled trial (RCT)
found no signiﬁcant difference in efﬁcacy between MMF
and intravenous cyclophosphamide in 41 patients with
microscopic polyangiitis (MPA) [6]. However, preliminary
reports suggest that the international MYCYC study has
failed to demonstrate non-inferiority of MMF and a stand-
ard glucocorticoid taper in comparison to intravenous
cyclophosphamide in 140 patients with MPA and granulo-
matosis with polyangiitis [7]; although a secondary end
Fig. 1. Glomerulus showing crescentic glomerulonephritis due to pauci-
immune ANCA-associated vasculitis, with a segmental area of thrombosis,
tuft disruption and cells in Bowman’s space (Haematoxylin and eosin
×400). Courtesyof Professor Alexander Howie.
Table 1. Causes and frequencyof crescentic glomerulonephritis in which
there are >50% glomerularcrescents
Pathological causes of crescentic
glomerulonephritis
Proportion of conditions
with >50% crescents
a (%)
Anti-GBM disease 85
ANCA-associated glomerulonephritis 50
Lupus Nephritis 13
Henoch Schonlein Purpura 10
IgA Nephropathy 4
aAdapted from Heptinstall’s Pathology of the Kidney 6th ed, 2007.
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onstrate non-inferiority, suggesting that MMF and more
liberal steroid dosing may be equivalent to pulsed cyclo-
phosphamide. However, this trial speciﬁcally excluded pa-
tients with RPGN or severe renal impairment (deﬁned as
an eGFR decline of >20% in prior 2 weeks or eGFR <15 mL/
min/1.73 m
2, respectively). MMF cannot therefore be re-
commended in cases of RPGN on the basis of current data.
Therapeutic Plasma Exchange
The landmark MEPEX trial, which included 137 patients
with severe renal AAV, demonstrated a signiﬁcant beneﬁt
from therapeutic plasma exchange (TPE) in comparison
with intravenous glucocorticoid [8]. Although mortality did
not differ between the two groups, renal survival in patients
who received TPE was more favourable at 3 and 12 months.
However, subsequent follow-up of this cohort found no dif-
ference in patient or renal survival after an average of
nearly 4 years; the overall mortality ratewas also unexpect-
edly high in both groups [9]. Additionally, a meta-analysis
of TPE in RPGN, which included nine trials and 387 patients
(the majority of whom had AAV or idiopathic renal vascu-
litis), concluded that there was insufﬁcient evidence to
demonstrate that TPE reduces the risk of a combined
outcome of ESRD and death. Although TPE was associated
with a signiﬁcant reduction in the risk of ESRD alone [rela-
tive risk (RR) 0.64], the available data were insufﬁcient to
determine this reliably [10]. Therefore, the long-term
beneﬁt of TPE in severe AAV is unknown at present. The
international PEXIVAS trial aims to address this uncertainty
by randomizing 500 patients with AAVand signiﬁcant renal
injury (eGFR <50 mL/min/1.73 m
2) or pulmonary haemor-
rhage to receive either TPE and glucocorticoids or glucocor-
ticoids alone. Outcome data will not be available for
another few years (NCT00987389, protocol in [11]).
Anti-TNFα Agents
Previous studies of anti-TNFα a g e n t si nA A Vh a v eb e e nc o n -
ﬂicting. The Phase 2, open-label ACTIVE trial suggested a
role for inﬂiximab as an adjunctive therapy in remission in-
duction of AAV [12]; however, a recent open-label trial in 33
patients with AAV (80% with renal involvement) showed no
beneﬁt from the addition of inﬂiximab to standard care,
despite the fact that the inﬂiximab group had milder renal
involvement at baseline (median eGFR 32.6 versus 13 mL/
min/1.73 m
2 in the inﬂiximab and standard therapy groups,
respectively [P = 0.005], of whom 10 were dialysis depend-
ent) [13]. No current trials of inﬂiximab in AAVare registered.
The 2005 ‘WGET’ trial [14] also failed to show a beneﬁt
from etanercept for remission maintenance in 180 pa-
tients with GPA, half of whom had renal involvement
(mean serum creatinine 164 versus 143 µmol/L in treat-
ment and control groups, respectively). No further studies
have been published using this agent.
More recently, a pilot Phase 2 study of adalimumab,a s
an adjunctive induction agent in 14 patients with renal
AAV (mean eGFR 17 mL/min/1.73 m
2) reported similar
efﬁcacy and safety to standard care [15]. The authors
suggest that this may be a viable steroid-sparing agent,
but this would need to be conﬁrmed in a larger trial.
Other agents
Complement antagonists: C5a, a cleavage product of C5, is
a powerful anaphylatoxin and chemoattractant. The C5a
receptor, also known as CD88, is expressed on the surface
of monocytes and neutrophils; its importance in the medi-
ation of MPO-induced CGN has been demonstrated in
animal studies [16]. CCX168 is an inhibitor of C5aR/CD88,
which has been found to attenuate MPO-induced CGN in
mice [17]. A Phase 2 RCT of CCX168 as a steroid-sparing
agent was recently presented in abstract form [18]; results
suggested superior remission induction in patients who re-
ceived CCX168. The CLEAR trial (NCT01363388) is currently
recruiting (n=60); however, patients with RPGN or eGFR
<30 mL/min/1.73 m
2 are excluded from this study.
Tocilizumab is an anti-IL 6 receptor monoclonal anti-
body. One report of successful use of this agent in a case
of MPAwith RPGN has been published [19]; however, there
are no trial data of its use in RPGN.
IgA Nephropathy/Henoch Schonlein Purpura
Some crescentic change can often occur in IgAN and
Henoch Schonlein Purpura (HSPN), but this rarely results in
an RPGN pattern. Signiﬁcantly less common are cases of
RPGN with severe crescentic change (<5% of patients),
which are generally associated with a poor prognosis in
small series. Previous reports have suggested a beneﬁt
from immunosuppression with glucocorticoids and cyclo-
phosphamide [20, 21]; however, even when this regimen
is used, the 1- and 5-year renal survival rates in one large
contemporary series of crescentic IgAN remained low at
65% and 28%, respectively [22]. The clinical outcomes of
adults with HSPN are worse than those of children [23].
Mycophenolate Mofetil
Recent publications have suggested that MMF may have a
role in the treatment of proliferative IgAN. A retrospective
study of 119 Chinese patients with crescentic IgAN receiv-
ing three different immunosuppressant regimes (MMF or
cyclophosphamide in combination with glucocorticoids
or glucocorticoids alone) concluded that the combination
of MMF and glucocorticoids was associated with the most
favourable renal outcome (5-year renal survival 95%, 80%
and 70% for MMF/glucocorticoids, cyclophosphamide/
glucocorticoids and glucocorticoids alone, respectively)
[24]. Differences in disease severity, as well as treatment
duration, between the MMFand cyclophosphamide groups
may limit the generalisability of these ﬁndings. In add-
ition, although all patients had evidence of CGN on renal
biopsy, the mean baseline eGFR was ∼90 mL/min/1.73 m
2,
suggesting milder renal injury. Other studies of MMF in
IgAN and HSPN are limited by their retrospective nature
and low proportion of patients with CGN [25].
Rituximab
There is one published report of successful use of rituxi-
mab in a patient with drug-induced HSP and crescentic
IgAN who was resistant to glucocorticoids cyclophospha-
mide and plasmapheresis. Serum creatinine was 177
µmol/L at presentation, and renal biopsy showed 38%
glomeruli with crescents; following treatment with
rituximab, serum creatinine fell to 141 µmol/L [26].
Therapeutic Plasma Exchange
A case series of patients with severe HSPN (mean eGFR 67
mL/min/1.73 m
2, six with endocapillary proliferation,
Rapidly progressive glomerulonephritis management 145three with extracapillary proliferation) treated with TPE
and glucocorticoids reported a response to therapy in 9
out of 11 patients [27]. After an average of 6 years follow-
up, two patients died, one of whom developed ESRD. No
other studies on TPE in adult HSPN have recently been
published.
Cyclophosphamide
One randomised open-label trial of cyclophosphamide in
HSPN has been published recently [28]. Fifty-four patients
with severe HSPN were randomized to treatment with glu-
cocorticoids alone or in combination with intravenous
cyclophosphamide. 89% of patients had renal biopsies, of
which 48% showed endocapillary proliferation and 33%
extracapillary proliferation. Baseline eGFR was 60 and 76
mL/min/1.73 m
2 in the glucocorticoid-only and cyclophos-
phamide groups, respectively (non-signiﬁcant difference).
The primary end point was complete remission at 6
months (deﬁned as BVAS 0). Improvement in renal func-
tion, renal survival and adverse events were secondary
end points. There were no differences between the two
groups in either primary or secondary end points (10%
and 12% remission induction at 6 months in glucocortic-
oid and cyclophosphamide groups, respectively; p =1.0);
one patient in each group developed ESRD during the
study period. The authors concluded that the addition of
cyclophosphamide provided no beneﬁt in these patients.
However, the two groups differed at baseline, with pa-
tients in the cyclophosphamide group being younger, less
hypertensive and with lower disease activity than those in
the steroid-only group. Additionally, the study was under-
powered, with an estimated sample of 200 patients
needed to detect a signiﬁcant difference.
Anti-GBM Disease
Anti-GBM disease is essential to diagnose and treat
rapidly as more advanced disease is associated with a
worse renal recovery. Standard therapy is with cyclophos-
phamide, glucocorticoids and TPE.
Rituximab
Evidence for the use of rituximab in the treatment of anti-
GBM disease is limited to case reports. In the past 5 years,
successful use of rituximab has been reported in seven
cases, who were either resistant to or intolerant of conven-
tional treatment [29–32]. Improvement in renal function
has been reported in three published cases. Shah et al. [30]
reported two cases, one of whom recovered from dialysis-
dependence to a serum creatinine of 260 µmol/L after
treatment, and another whose creatinine fell from 272 to
100 µmol/L after treatment. Bandak et al. [31] reported a
patient who was dialysis dependent at presentation and
had a serum creatinine of 182 µmol/Lafter treatment.
Mycophenolate Mofetil
MMF has also been successfully used in refractoryor relaps-
ing anti-GBM disease, but the evidence base for this agent
does not extend beyond single case reports [33–35].
Therapeutic Plasma Exchange
The efﬁcacyof TPE in anti-GBM disease was ﬁrst suggested
by an observational study of seven patients in 1976 [36].
The largest case series of patients treated with TPE was
published by Levy et al.[ 37] in 2001; these patients also
received oral glucocorticoids and cyclophosphamide. More
recently, a large retrospective study of 221 patients in
China reported more favourable clinical outcomes in pa-
tients treated with a combination of TPE, cyclophospha-
mide and glucocorticoids, compared with those who
received either cyclophosphamide and glucocorticoids or
glucocorticoids alone [38]. There were differences
between the groups at baseline, and less than half of the
patients in the study underwent renal biopsy.
Other Forms of Extracorporeal Blood Puriﬁcation
Immunoadsorption has been proposed as a more efﬁcient
method for removing anti-GBM antibodies. A case series of
10 patients reported good patient and renal survival (90%
and 63%, respectively) at 1 year; the efﬁciency of antibody
removal was superior to that typicallyseen in TPE, however,
an average of 22 sessions per patient were required [39].
Double-ﬁltration plasmapheresis (DFPP) selectively
removes immunoglobulins and involves replacement of
much lower volumes of plasma than standard TPE (typic-
ally 15%). A comparison of DFPP with immunoadsorption
found similar patient and renal survival, and a similar efﬁ-
cacy of antibody removal, in 28 patients with severe anti-
GBM disease in China [40].
Combination haemodialysis and plasma exchange offers
a possible beneﬁt of reducing therapy time and manpower
in patients who require both treatment modalities due to
the severity of their disease as is often seen in anti-GBM
disease. The largest case series of this combination
therapy was published last year [41]. This included 24 pa-
tients with anti-GBM disease and 25 with AAV, treated
over an 18-year period in a single centre in Canada. Renal
recovery and patient survival were comparable to previ-
ously published studies (13% and 75% for anti-GBM
disease; 8% and 96% for AAV, respectively), and the safety
proﬁle was acceptable.
Lupus Nephritis
RPGN occurs in a small proportion of patients with system-
ic lupus erythematosis (SLE) and accounts for a persistent
number of patients reaching ESRD despite conventional
treatment. These patients may have fewer extra-renal
symptoms and more frequently are also positive for ANCA
[42] and anti-C1q antibodies [43, 44].
There are manystudies in progress or recently published
on LN, some of which report promising ﬁndings. However,
most trials speciﬁcally exclude patients with RPGN or
severe renal impairment. The evidence base for this subset
of patients istherefore relativelysmall.
A retrospective study in China examined the clinical
characteristics and outcomes of 33 patients with cres-
centic LN, using 119 patients with non-crescentic LN as a
comparator group [42]. All patients received combinations
of glucocorticoids cyclophosphamide and MMF, in an uncon-
trolled manner. Unsurprisingly, the presence of crescents
was associated with more severe renal injury, less favourable
response to therapy, higher relapse rates and lower renal
survival; patient survival was unaffected. Another study in
China reported that renal outcomes in 620 patients with
Class IV LN correlated with the percentage of histological
crescents [43]. Statistical signiﬁcance was not reported in
this study, and treatment protocols varied.
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Although earlier case series and pilot studies suggested
that rituximab might be effective in the treatment of LN,
well-designed RCTs subsequently failed to demonstrate a
beneﬁt. The EXPLORER trial showed no beneﬁt of rituxi-
mab over placebo in moderate-to-severe extra-renal SLE
[45]. The LUNAR trial [46] of 144 patients with Class III or
IV LN in the USA and Latin America who were randomized
to receive either rituximab or placebo in combination with
MMF and glucocorticoids also found no difference in the
primary end point of renal response at 1 year. Patients
with eGFR <25 mL/min/1.73 m
2 were excluded; mean
baseline eGFR was around 90 mL/min/1.73 m
2. The pro-
portion of patients in this study with crescentic LN was not
reported, but it is likely to be low.
Davies et al. reported a poor response to combination
therapy with rituximab, low-dose intravenous cyclo-
phosphamide and intravenous glucocorticoids in an open-
label study of 18 patients with Class III–V lupus nephritis
who had failed conventional therapy. Although the overall
response rate was good (13 out of 18 responded by 6
months), the patients with RPGN fared relatively poorly. All
four of the patients with severe proliferative crescentic
LN (mean crescents 71%, mean creatinine 178 µmol/L)
showed no response and rapidly progressed to ESRD [47].
A retrospective observational study of 20 patients who
received rituximab for active Class III–V LN in France
reported an overall renal response of 60% after a median
of 22 months follow-up [48]. All patients in this study had
received standard immunosuppression prior to rituximab
initiation, consisting of cyclophosphamide, glucocorticoids
and MMF. Renal insufﬁciency (eGFR <60 mL/min/1.73 m
2)
was present in nine patients. Three patients had evidence
of RPGN. None of these patients responded to treatment:
two were dialysis dependent at presentation and never
recovered; one had severe renal insufﬁciency (eGFR
16 mL/min/1.73 m
2) and progressed to ESRD 6 months
after rituximab initiation.
An analysis of pooled data from patients with LN
treated with rituximab across Europe found that renal im-
pairment (deﬁned as eGFR <60 mL/min/1.73 m
2) was as-
sociated with a lower chance of achieving complete
remission (15% versus 35% chance of complete recovery
for eGFR below and above 60 mL/min/1.73 m
2, respective-
ly, p<0.05), suggesting that RPGN secondary to LN does
not respond well to rituximab [49]. Patients with types III–
V LN were included, but the number of patients with CGN
was not reported.
In summary, there does not appear to be sufﬁcient pub-
lished evidence supporting a beneﬁcial effect of rituximab
in crescentic LN.
Mycophenolate mofetil
A retrospective study of 52 patients in China with cres-
centic LN (>50% crescents on biopsy) compared the out-
comes of patients treated with MMF (n= 27) and
intravenous cyclophosphamide (n= 25) [50]. Both groups
received pulsed glucocorticoids at induction, followed by
maintenance therapy with low-dose oral prednisolone
and Tripterygium wilfordii (a traditional Chinese herbal-
derived medication). Most patients had signiﬁcant renal
insufﬁciency at baseline (two-thirds had creatinine >110
µmol/L, one-quarter >267 µmol/L). More patients in the
MMF group than in the cyclophosphamide group achieved
a complete remission at 12 months (54% versus 26%, p =
0.047), and the relapse rate in the MMF group was signiﬁ-
cantly lower than the cyclophosphamide group (11%
versus 44%, signiﬁcance not reported). Adjunctive therapy
was not reported in this study, so it is difﬁcult to draw ﬁrm
conclusions about the relative merits of the drugs studied.
Tacrolimus
A recent randomised trial compared induction using tacroli-
mus with MMF in 150 patients with Class III–V LN who also
received glucocorticoids. Complete renal remission and a
composite outcome of chronic kidney disease (Stage 4–5),
reduction of creatinine clearance by 30% or death, were
equal in the two arms. However, patients were excluded if
creatinine was >200 µmol/L [51]. Morimoto et al.[ 52]r e -
ported a case of LN and RPGN with 39% crescents, in asso-
ciation with an MPO-ANCA, who received limited treatment
with cyclophosphamide and azathioprine due to adverse
effects. The patient went on to receive glucocorticoids and
tacrolimus, and successful disease remission was achieved.
In a randomised trial comparing intravenous cyclophos-
phamide and steroids with combined treatment of MMF, ta-
crolimus and glucocorticoids in LN, there was a greater
number of patients achieving complete remission at 6
months in the combination group; however, patients with
serum creatinine >265 µmol/L were excluded [53]. One
patient with crescentic LN (61% crescents) was separately
reported to have successfully entered remission using this
multi-targeted approach [54].
Ocrelizumab
Ocrelizumab is an anti-CD20 monoclonal antibody with
some evidence of efﬁcacy in rheumatoid arthritis. A
placebo-controlled trial of its use in type III–V LN was ter-
minated early due to serious infections in the intervention
arm; outcome data did not demonstrate a clear beneﬁto f
this agent [55]. Patients with severe renal impairment
(eGFR<25 mL/min/1.73 m
2) were excluded from this
study. It is unlikely that this agent will have a role in the
treatment of crescentic LN.
Belimumab
Belimumab is an anti-soluble B-lymphocyte stimulator,
which has been shown to be effective in two large RCT’so f
extra-renal SLE (BLISS-52 [56] and BLISS-76 [57]). Patients
with active severe LN were excluded from these studies.
An RCT of this agent in active LN is currently underway
(NCT01639339). This study may include some patients
with RPGN; patients requiring dialysis are excluded. A
safety and efﬁcacy study of the addition of belimumab to
rituximab and cyclophosphamide in active proliferative LN
has recently commenced (NCT02260934); patients with
eGFR <20 mL/min/1.73 m
2 are excluded.
Potential novel uses of current drugs for treatment
of RPGN
Fostamatinib is a spleen tyrosine kinase inhibitor, which
blocks intracellular signalling and Fc receptor activation.
There is some evidence of beneﬁt from this agent in
rheumatoid arthritis. Experimental evidence has shown
that the agent can completely prevent induction of anti-
GBM disease, and delayed administration results in cessa-
tion of autoantibody production, reversal of renal injury
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believed to be mediated by impaired activity of antigen-
speciﬁc B cells, as well as effects on cell-mediated
immunity [58, 59]. A Phase 2 trial of treatment for IgAN
commenced in 2014; however, patients with RPGN are
excluded (NCT02112838).
Imatinib is a tyrosine kinase inhibitor with speciﬁcity for
c-Abl, c-Kit and platelet-derived growth factor receptors,
which is used in the treatment of certain leukaemias and
GIST tumours. Delayed administration has been shown to
attenuate acute injury and chronic damage in experimen-
tal anti-GBM disease [60, 61]. It may exert its beneﬁcial
effect by targeting activated parietal epithelial cells as well
as monocytes/macrophages. A single case report of its suc-
cessful use in type 2 cryoglobulinaemia with membrano-
proliferative glomerulonephritis (MPGN) has been published
(peak creatinine 248µmol/L, ﬁnal creatinine 133 µmol/L)
[62], but no trials are registered for its use in RPGN.
Bortezomib (velcade) is a protease inhibitor, which
targets plasmablasts and mature plasma cells. It has es-
tablished use in myeloma and has been shown to be ef-
fective in murine models of LN and MPO-associated NCGN
[63]. A pilot study of the use of this agent in severe IgAN is
underway in the USA (NCT01103778). The potential
beneﬁt of other protease inhibitors in autoantibody-
mediated diseases, such as SLE, is also being tested.
Erlotinib is an epithelial growth factor receptor (EGFR)
tyrosine kinase inhibitor used for the treatment of various
malignancies. Podocyte and parietal epithelial cell EGFR
expression is augmented in human and murine CGN
[64, 65]. Delayed administration of erlotinib attenuates
renal injury in an experimental mouse model of anti-GBM
disease [66]. There are no trials registered for RPGN, but
this may represent a promising agent.
Eculizumab is a monoclonal antibody that blocks cleav-
age of C5 to C5a, reducing complement activation via the
alternative pathway. It has been shown to be effective in
the treatment of atypical HUS and paroxysmal nocturnal
haemoglobinuria, conditions characterised by inappropri-
ate activation of the complement system. It has been
proposed that it may also beneﬁt patients with IgAN [67]
or immune complex disease; however, there are no trials
registered for this use at present.
Future potential therapies
Programmed Death-1 Receptor
The programmed death-1 (PD-1) receptor is a member of
CD28 family, which is preferentially expressed on activated
T-cells and is important in the maintenance of tolerance.
PD-1 stimulation causes reduced proliferation and cytokine
expression. Delayed stimulation using a PDL-1/Fc fusion
protein attenuates a rat anti-GBM model by inhibiting cell-
mediated immunity only, with no effect on antibody pro-
duction or glomerular IgG deposition [68]. No PD-1 agonists
are currentlyavailable forclinical use.
C-jun Amino Terminal Kinase (JNK) Signalling
Macrophage JNK signalling is thought to playa pathogenic
role in anti-GBM disease [69]. Administration of a JNK
inhibitor on Day 7–24 attenuates experimental anti-GBM
disease via a mechanism independent of humoural
immunity [70]. Early dose-ﬁnding studies are underway at
present.
Seleciclib (Roscovitine)
Seleciclib is a cyclin-dependent kinase inhibitor with evi-
dence for a beneﬁcial role in various animal models of GN
(MPGN, membranous nephropathy, LN). It attenuates rat
anti-GBM when used as treatment, possibly by inﬂuencing
glomerular macrophage inﬁltration [76].
Stem Cell Therapy
Stem cell therapy is at an early phase of development, but
it may offer a future therapeutic strategy in immune-
mediated renal disease (reviewed in [71]). There is some
experimental evidence in animal models of anti-GBM
disease, where investigators have used mesenchymal
stem cells, which are progenitors of renal tissue, with
some success [72–74]. A case of NCGN due to MPA suc-
cessfully treated with stem cell therapy has been reported
[75]. The patient’s serum creatinine peaked at 690 µmol/L;
standard therapy with cyclophosphamide and glucocorti-
coids was ineffective, and rituximab was not tolerated; fol-
lowing treatment with autologous mesenchymal stem
cells, the patient’s creatinine fell to 168 µmol/L in parallel
with a reduction in the ANCA titre.
In summary, several novel targets and potential thera-
peutic agents show some promise for the treatment of
CGN, but theirclinical role is yet to be determined.
Conclusions
Although there is a paucity of randomised trial data, the
role of commonly used immunosuppressant agents in
CGN is becoming clearer. Publication bias and the rarity
of the diseases involved mean that international colla-
borations and sharing of data using clinical registries are
essential for the clinical and academic communities to in-
crease understanding and reﬁne therapeutic protocols.
Advances in our understanding of the pathogenesis of
various forms of CGN have led to the discovery of novel
therapeutic targets, and the use of agents already estab-
lished for the treatment of other diseases shows some
promise; however, we are some way from the widespread
clinical implementation of these treatments. The results
of early clinical trials of newer agents, as well as larger
multi-centre trials designed to clarify the role of estab-
lished therapies such as TPE are eagerlyawaited.
Conﬂict of interest statement. None declared.
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